MDS risk stratification and curative treatment
The Expanding Role of HCT with IPSS-M
Release date: July 31, 2023
Access on-demand webinar
Interested in claiming CME or CE credit?
Be sure to complete the pre-test here, then complete the post-test after watching the webinar. The post-test link can be found in the on-demand webinar platform in the related resources tab. For more information, see the instructions for participation and requesting credit below.
Target Audience
This educational activity is intended for physicians, nurses, and other members of the health care team who care for patients who may benefit from hematopoietic cell transplantation (HCT).
Program Overview
This webinar will focus on recent advances in the risk stratification of myelodysplastic syndrome (MDS) and the expanding role of allogeneic HCT as the only curative therapy for MDS. With the International Prognostic Scoring System (IPSS) evolving over the last few years from the revised IPSS (IPSS-R) to the inclusion of molecular disease markers (IPSS-M), more patients than before are being identified as having medium to high-risk MDS. This risk classification is one of the main eligibility criteria for the HCT in MDS. Additionally, advances that have greatly expanded the access of HCT to older patients are not necessarily being reflected in HCT referral patterns. Highlighting results from recently published studies on the development of the IPSS-M, referral patterns for HCT in MDS, and the latest consensus guidelines for the use of HCT in MDS treatment from the American Society for Transplantation and Cellular Therapy (ASTCT), our transplant and hematology/oncology panelists will discuss the current state of HCT eligibility and when to consider HCT for patients with MDS.
During this interactive webinar, our expert transplant and hematology/oncology panelists will discuss implications for practice change in the risk stratification and eligibility of patients with MDS for HCT, as well as ways to improve access to this curative therapy. This discussion will be tailored for hematologists/oncologists who refer out for transplant and cellular therapies as well as for transplant physicians to highlight the role of sharing care to improve patient access and outcomes.
Learning Objectives
Upon completion of this course, the learners should be able to:
- Explain the latest consensus treatment recommendations for MDS and indications for HCT
- Identify referral patterns and challenges in the management and treatment of MDS
- Discuss advances in MDS risk stratification that expand HCT eligibility
- Recognize how advances in HCT facilitate improved survival and preserve quality of life
- Describe the role of transplant and hematology/oncology physicians in improving access to HCT for those with MDS
Faculty
Steven Devine, MD (moderator)
Chief Medical Officer
National Marrow Donor Program® (NMDP)/Be The Match®
Associate Scientific Director
CIBMTR-NMDP/Be The Match
Robert P. Hasserjian, MD
Professor of Pathology
Director, Hematopathology Fellowship, Department of Pathology
Massachusetts General Hospital
Andrew Brunner, MD
Assistant in Medicine, Division of Hematology/Oncology
Massachusetts General Hospital
Assistant Professor
Harvard Medical School
Bart L. Scott, MD
Professor, Transplantation Program
Clinical Research Division
Fred Hutch Cancer Center
Planning Committee
Alice Houck, MPS
Senior Director of Patient and Health Professional Services
Aplastic Anemia and MDS International Foundation (AAMDSIF)
Anna Cincotta, FNP
Senior Clinical Operations Partner
National Marrow Donor Program (NMDP)/ Be The Match
Samantha Watters, MPH
Research and Education Lead
Community Physician Engagement
NMDP/Be The Match
Stephen Spellman, MBS
Vice President of Research and Senior Scientific Director
CIBMTR® (Center for International Blood and Marrow Transplant Research®)
NMDP/Be The Match
Instructions for Participation and Requesting Credit
There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the pre-test, completing the activity, and completing the post-test and evaluation form. A score of at least 75% on the posttest is required to successfully complete this activity. The participant may take the test until successfully passed.
Credit fulfillment
- If you are requesting AMA credits, ANCC credits, or a certificate of participation, your certificate will be available for download.
Technical Requirements
This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox and Safari browsers.
Additionally, this site and its activities are best viewed using the latest Operating System for your device.
Accredited Provider
Accredited Provider
This activity is jointly provided by The France Foundation and the National Marrow Donor Program (NMDP)/Be The Match.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by The France Foundation and the National Marrow Donor Program (NMDP)/Be The Match. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The France Foundation designates this activity for 1.0 contact hour.
All other health care professionals completing this course will be issued a statement of participation.
Disclosure Policy
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) and the National Marrow Donor Program (NMDP)/Be The Match require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF and NMDP/Be the Match resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and NMDP/Be The Match to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and NMDP/Be The Match committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.
| Name of Individual | Individual’s Role in Activity | Name of Commercial Entity | Nature of Relationship(s) | Mechanism(s) implemented to resolve conflict of interest |
|---|---|---|---|---|
| Anna Cincotta, FNP | Planning Committee, Content Reviewer | No relevant financial disclosures | NA | NA |
| Heather Stefanksi, MD, PhD | Planning Committee, Content Reviewer | 1. Novartis | 1. Non-CE Consulting | The financial relationship with Novartis ended in April 2021. |
| Heather Tarbox, MPH | TFF Staff | No relevant financial disclosures | NA | NA |
| Jas Chahal, PhD | TFF Staff | No relevant financial disclosures | NA | NA |
| Karla Dawson, MPH | NMDP Staff | No relevant financial disclosures | NA | NA |
| Kelly Wilson, MSN, RN | NMDP Staff | No relevant financial disclosures | NA | NA |
| Mary Horowitz, MD, MS | Planning Committee, Faculty | 1. Astellas, Gamida Cell Ltd, Genentech, Magenta, OncoImmune | 1. Research |
The financial relationship with Astella, Genentech, Magenta, and OncoImmune ended prior to June 2022. Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning. |
| Nandita Khera, MD, MPH | Planning Committee, Faculty | 1. Optum | 1. Honoraria | The financial relationship with Optum ended prior to June 2022. |
| Samantha Watters, MPH | Planning Committee, Faculty | No relevant financial disclosures | NA | NA |
| Stephen Spellman, MBS | Planning Committee Member, Moderator | No relevant financial disclosures | NA | NA |
| Vamsi Kota, MD | Planning Committee, Faculty | 1. Novartis, Pfizer | 1. Honoraria | Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning. |
Disclosure of Unlabeled Use:
TFF and NMDP/Be The Match require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and NMDP/Be The Match do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
TFF and NMDP/Be The Match present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, NMDP/Be The Match, and the commercial supporter(s) assume no liability for the information herein.
Copyright Information
Copyright © 2023 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:
- The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
- Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.
Privacy Policy
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.
The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.
Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy.
Contact Information
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com. Please review this information, and proceed below